Investor presentation for the quarter ended on June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals filed its Q1 FY26 investor presentation detailing its four-entity group structure: listed parent BPL, US/EU-focused specialty CDMO Innoxel Lifesciences (55.9% subsidiary, USFDA inspection cleared in May 2025), emerging-markets complex injectables arm Varenyam Bio (targeting FY27 operations), and Indian branded generics arm Varenyam Healthcare (targeting ₹100 Cr revenue by FY28). On a standalone basis, Q1 FY26 revenue was flat YoY at ₹95.8 Cr while EBITDA margin expanded to 16.33% (vs 16.28%). On a consolidated basis, revenue grew 23.2% YoY to ₹117 Cr and EBITDA surged 207% YoY to ₹13.8 Cr as Innoxel's losses narrowed sharply. Management guided FY26 standalone revenue growth of 12-14% and EBITDA margin improvement to 15-17%, supported by a strong order book and better product mix. Innoxel is expected to generate ₹65-70 Cr revenue in FY26 and commercial CMO supplies are slated to begin from Q1 FY27 after an EU-GMP inspection in FY26.
Positive read for shareholders — explicit margin expansion guidance (15-17% from current ~11-16%) and disciplined revenue growth outlook point to operating leverage playing out, while the subsidiaries' revenue activation timeline (Innoxel CMO from Q1 FY27, Varenyam Bio from FY27) provides clear multi-year growth catalysts that could re-rate the stock beyond the standalone business.